Anti-Human IL13 Recombinant Antibody (Anrukinzumab) (CAT#: TAB-H05)

Recombinant Humanized (from mouse) antibody to Human IL13. Anrukinzumab (IMA-638) is a humanized monoclonal antibody designed for the treatment of asthma.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Tested Data
  • Gene Expression
  • Datasheet
  • MSDS
  • COA
ELISA

Figure 1 Visual predictive check for the final model stratified by dose.

Figure 1 Visual predictive check for the final model stratified by dose.

Examples included is 200 mg i.v. (study 5, UC patients).

Hua, F., Ribbing, J., Reinisch, W., Cataldi, F., & Martin, S. (2015). A pharmacokinetic comparison of anrukinzumab, an anti‐IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. British journal of clinical pharmacology, 80(1), 101-109.

ELISA

Figure 2 Concentration vs. time profiles of anrukinzumab given as multiple i.v. 200 mg doses to UC patients or non-UC subjects.

Figure 2 Concentration vs. time profiles of anrukinzumab given as multiple i.v. 200 mg doses to UC patients or non-UC subjects.

Hua, F., Ribbing, J., Reinisch, W., Cataldi, F., & Martin, S. (2015). A pharmacokinetic comparison of anrukinzumab, an anti‐IL‐13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. British journal of clinical pharmacology, 80(1), 101-109.

Inhib

Figure 3 Effect of anrukinzumab compared with placebo on fold change in faecal calprotectin.

Figure 3 Effect of anrukinzumab compared with placebo on fold change in faecal calprotectin.

Reinisch, W., Panés, J., Khurana, S., Toth, G., Hua, F., Comer, G. M., ... & Zhu, H. (2015). Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut, 64(6), 894-900.

Inhib

Figure 4 Median total IL-13 level versus time profile by treatment group.

Figure 4 Median total IL-13 level versus time profile by treatment group.

Reinisch, W., Panés, J., Khurana, S., Toth, G., Hua, F., Comer, G. M., ... & Zhu, H. (2015). Anrukinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. Gut, 64(6), 894-900.


Specifications

  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • IgG1
  • Specificity
  • IL13 (interleukin 13, IL-13) [Homo sapiens]
  • Species Reactivity
  • Human
  • Applications
  • ELISA, Inhib
  • CAS
  • 910649-32-0
  • Generic Name
  • anrukinzumab
  • UNII
  • OU46IGC49F
  • MW
  • 145.4 kDa
  • Related Disease
  • Ulcerative colitis (UC)

Product Property

  • Purity
  • >95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.

Applications

  • Application Notes
  • The Human IL13 antibody has been reported in applications of Enzyme-linked Immunosorbent Assay, Inhibition.

Target

  • Alternative Names
  • anrukinzumab;910649-32-0;IMA-638;IL13;interleukin 13;interleukin-13;allergic rhinitis;ALRH;BHR1;Bronchial hyperresponsiveness 1 (bronchial asthma);IL 13;MGC116786;MGC116788;MGC116789;P600;Bronchial hyperresponsiveness-1 (bronchial asthma);IL-13;

Related Resources

  • Biosimilar Overview
  • Related Diseases
Please refer to Anrukinzumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Anrukinzumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Anrukinzumab"

Afuco™ Anti-IL13 ADCC Recombinant Antibody (Anrukinzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant Humanized (from mouse) antibody to Human IL13. Anrukinzumab (IMA-638) is a humanized monoclonal antibody designed for the treatment of asthma.

See other products for "IL13"

Recombinant Antibody

Human Antibody

Chimeric Antibody

CAT Product Name Application Type
TAB-094ZJ Anti-Human IL-13 Recombinant Antibody (167) ELISA Chimeric antibody (mouse/human)
TAB-094ZJ-S(P) Anti-Human IL-13 Recombinant Antibody scFv Fragment (167) ELISA Chimeric antibody (mouse/human)
TAB-094ZJ-F(E) Anti-Human IL-13 Recombinant Antibody Fab Fragment (167) ELISA Chimeric antibody (mouse/human)

Rabbit Monoclonal Antibody

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-H05 Afuco™ Anti-IL13 ADCC Recombinant Antibody (Anrukinzumab), ADCC Enhanced FC, IP, ELISA, Neut, FuncS, IF ADCC enhanced antibody
AFC-TAB-017ML Afuco™ Anti-IL13 ADCC Recombinant Antibody (Dectrekumab), ADCC Enhanced ELISA, IHC, FC, IP, IF, Inhib ADCC enhanced antibody
AFC-TAB-219 Afuco™ Anti-IL13 ADCC Recombinant Antibody (Lebrikizumab), ADCC Enhanced ELISA, Neut, IF, IP, FC, FuncS ADCC enhanced antibody
AFC-TAB-218 Afuco™ Anti-IL13 ADCC Recombinant Antibody (Tralokinumab), ADCC Enhanced ELISA, FC, IP, FuncS, IF, Neut ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-H05. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare